IL5 and asthma: The objective of this observational study was to identify and describe patients with severe asthma (as defined by International European Respirology Society (ERS)/American Thoracic Society (ATS) guidelines [1]), who are eligible for biologic therapy, and identify the proportion of patients eligible for targeting IgE, IL-5, or both pathways of immunomodulation.